Riyadh, Saudi Arabia 10/12/2024— MS Pharma, a leader in pharmaceutical innovation across the Middle East and North Africa, showcased its cutting-edge biologics portfolio and state-of-the-art biosimilar manufacturing facility at CPhI Middle East 2024. The event, held from December 10–12 at the Riyadh Front Exhibition & Convention Center, is recognized as the premier gathering for global pharmaceutical leaders.

Riyadh, Saudi Arabia – MS Pharma, a leading pharmaceutical company in the MENA region, has signed an Industry Localization and Knowledge Transfer Agreement with the Local Content and Government Procurement Authority (LCGPA) in Saudi Arabia. The agreement, formalized during the Local Content Forum 2024 in Riyadh, marks an important milestone with the inclusion of the Ranibizumab liquid vial product in the Mandatory List.

MS Pharma has partnered with Saudi Arabia’s LCGPA to localize production and share expertise. The agreement, announced at the 2024 Local Content Forum in Riyadh, adds the Ranibizumab liquid vial to the Mandatory List.

Baghdad, Iraq, MS Pharma, a leading pharmaceutical company in the Middle East and North Africa (MENA), is pleased to announce a significant meeting held on 5th June 2024 between the Iraqi Minister of Health, Dr. Saleh Mahdi Al-Hasnawi, and a delegation from MS Pharma, headed by CEO Kalle Känd. The meeting focused on exploring ways to enhance cooperation in the pharmaceutical industry, with a special emphasis on supporting and localizing the pharmaceutical industry within Iraq. The meeting is part of the Iraqi government initiative to support national industries, particularly the pharmaceutical sector.

Riyadh, KSA – MS Pharma, a leading pharmaceutical company in the MEA region, hosted a lecture covering advances in retinopathy management. During the event, the launch of Ravegza® (Ranibizumab FYB201), an innovative biosimilar medicine for treating retinal diseases, including diabetic retinopathy (DR) and wet age-related macular degeneration (AMD), was announced. This follows the recent approval of Ravegza® (Ranibizumab FYB201), by the Saudi Food and Drug Authority (SFDA) three months ago.